# Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

> **NCT05958719** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 37 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma
- Epigenetic Repression

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Azacitidine
- **DRUG:** liposomal mitoxantrone
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT05958719
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-02
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-03-02
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05958719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05958719, "Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05958719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*